Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Cardiologists develop new AI screening tool for structural heart disease
Researchers have developed an advanced AI model capable of detecting signs of severe AS, mitral regurgitation and other complications in ECG results. For example, one 84-year-old patient who was hospitalized for a fractured femur ended up being scanned and treated with TAVR just days later.
World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs
The new-look TAVR system was linked to multiple benefits after one year. The cardiologists evaluating this device belief it could significantly reduce the risk of long-term valve degeneration.
Heart failure biomarker identifies long-term risk in T-TEER patients
NT-proBNP measurements are often used to diagnose and manage heart failure. According to a new study of more than 2,000 patients, they can also provide value to cardiologists performing T-TEER.
Cardiologists perform first TAVR of its kind by anchoring valve to crushed stent
The patient, 78, presented with severe AR and no signs of calcification. She was considered a poor choice for surgery or traditional TAVR due to multiple risks. That is where the new-look ATLAS technique came in.
3D software helps cardiologists plan ahead for TAVR complications
Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues.

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR

Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.

Gore completes acquisition of medtech company behind next-gen heart device

Gore has officially acquired Conformal Medical, the company known for an investigational LAAO device that uses a proprietary foam implant. The transaction was first announced in January.

After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way

Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.

REVENUE MONEY INCREASE DOLLAR GRAPH FINANCE

Edwards celebrates double-digit TAVR sales growth in Q4

It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry.

Stroke risk after TAVR still higher for woman as ‘sex paradox’ lives on

By tracking sex-related differences after TAVR, researchers hope to refine patient selection strategies and optimize care for both men and women.

Structural Heart Disease

Cardiologists develop new AI screening tool for structural heart disease

World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs

Heart failure biomarker identifies long-term risk in T-TEER patients

Cardiologists perform first TAVR of its kind by anchoring valve to crushed stent

3D software helps cardiologists plan ahead for TAVR complications